Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)

Sueh-Li Lim, John Reynolds, Lucy Pemberton, Tricia Wright, Sophie Lee, Peter Mollee, Anita C. Shetty, Yu Jin Kim, Weston Helen, Byard Nina, Khoa Le, Zoe McQuilten, Hang Quach, Andrew Spencer

Blood (2025) 146 (Supplement 1): 5842.

https://doi.org/10.1182/blood-2025-5842

Published: 2025

Journal Articles

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)

Blood (2025) 146 (Supplement 1): 4039.

https://doi.org/10.1182/blood-2025-4039

Published: 2025

Journal Articles

Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups.

Ghassan Zammar, Bradley Augustson, Elizabeth Moore, M Hasib Sidiqi, Cameron Wellard, Elham Ashrafi, Simon Harrison, Dejan Radeski, Alannah Jackson, Krystal Bergin, Phoebe Joy Ho, Tracy King, Peter Mollee, Hang Quach, Rajeev Rajagopal, Zoe McQuilten, Erica Wood, Brian Rosengarten, Andrew Spencer

Blood (2025) 146 (Supplement 1): 2221.

https://doi.org/10.1182/blood-2025-2221

Published: 2025

Journal Articles

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Blood (2025) 146 (Supplement 1): 692.

https://doi.org/10.1182/blood-2025-692

Published: 2025

Journal Articles

Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis

Nirija Ranjit Anderson, Sharmila Dorbala, Peter Mollee

Blood (2025) 146 (10): 1157–1162.

https://doi.org/10.1182/blood.2024026386

Published: 2025

Journal Articles

Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis

Betty Gration, Cameron Wellard, Elizabeth Moore, Marianne Tan, Matthew Murphy, Kenneth J C Lim, James Rowland, Nada Hamad, Rajeev Rajagopal, Peter Mollee, Andrew Spencer, Hang Quach, Georgia McCaughan

Blood (2024) 144 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2024-201790

Published: 2024

Journal Articles

Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, Betty Gration, Bradley Augustson, Peter Mollee, Jennifer Zhang, Nicole Wong Doo, Sabine Ringkowski, Adam Bryant, Slavisa Ninkovic, Nada Hamad, Georgia McCaughan, Shaji Kumar, Andrew Spencer, Hang Quach

Blood (2024) 144 (Supplement 1): 1951.

https://doi.org/10.1182/blood-2024-207609

Published: 2024

Journal Articles

Plasma Cell Enumeration By Manual and Automated Methods to Establish a Standard Pictorial Reference

Aarya Murali, Joshua W.D. Tobin, Peter Mollee

Blood (2024) 144 (Supplement 1): 7585.

https://doi.org/10.1182/blood-2024-204199

Published: 2024

Journal Articles

Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)

Betty Gration, Cameron Wellard, Elizabeth Moore, Peter Mollee, Ian H. Kerridge, Andrew Spencer, Anita Shetty, Bart Baker, Cecily Forsyth, Jessica Heenan, Zoe K McQuilten, Erica M. Wood, Georgia McCaughan

Blood (2024) 144 (Supplement 1): 5147.

https://doi.org/10.1182/blood-2024-199451

Published: 2024

Journal Articles

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Blood (2024) 144 (Supplement 1): 892.

https://doi.org/10.1182/blood-2024-204700

Published: 2024

Journal Articles

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Blood (2024) 144 (Supplement 1): 891.

https://doi.org/10.1182/blood-2024-205077

Published: 2024

Journal Articles

Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Sueh-Li Lim, John Reynolds, Lucy Pemberton, Tricia Wright, Sophie Hyesuk Lee, Peter Mollee, Anita C Shetty, Helen Weston, Nina Byard, Khoa Le, Zoe K McQuilten, Hang Quach, Andrew Spencer

Blood (2024) 144 (Supplement 1): 4755.

https://doi.org/10.1182/blood-2024-209640

Published: 2024

Journal Articles

Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment Accuracy

Nirija Ranjit Anderson, W. Phillip Law, Xin Dong, Arnold C.T Ng, Peter Mollee

Blood (2023) 142 (Supplement 1): 6744.

https://doi.org/10.1182/blood-2023-186377

Published: 2023

Journal Articles

Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy

Anthea Gibbons, Nirija Ranjit Anderson, Lipi Chakravorty, Fiona Kwok, Hasib Sidiqi, Simon Gibbs, Dariusz Korczyk, Emad Uddin Abro, Peter Mollee

Blood (2023) 142 (Supplement 1): 2030.

https://doi.org/10.1182/blood-2023-179219

Published: 2023

Journal Articles

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

Blood (2023) 142 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2023-185169

Published: 2023

Journal Articles

High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL

Muhammed B. Sabdia, Melinda Burgess, Soi Cheng Law, Lauren A Thurgood, Stephen Kazakoff, Fiona Swain, Joshua W.D. Tobin, Peter Mollee, Ann-Marie Patch, Maher K Gandhi

Blood (2023) 142 (Supplement 1): 3260.

https://doi.org/10.1182/blood-2023-174149

Published: 2023

Journal Articles

Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries

Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, Slavisa Ninkovic, Wee-Joo Chng, Andrew Spencer, Peter Mollee, Jay Hocking, Phoebe Joy Ho, Wojt Janowski, Kihyun Kim, Karen Dun, Zoe K McQuilten, Fiona Chen, Hang Quach

Blood (2023) 142 (Supplement 1): 3325.

https://doi.org/10.1182/blood-2023-173896

Published: 2023

Journal Articles

A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma

Andy Tang, Kihyun Kim, Fiona Chen, Zoe K McQuilten, Peter Mollee, Rajeev Rajagopal, Hang Quach, Phoebe Joy Ho, Simon J. Harrison, Andrew Spencer, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2023-178192

Published: 2023

Journal Articles

Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen

Lipi Chakravorty, Anthea Gibbons, Nirija Anderson, Fiona Kwok, Dariusz Korczyk, Emad Uddin Abro, Stephanie Lam, Simon Gibbs, Peter Mollee, M Hasib Sidiqi

Blood (2023) 142 (Supplement 1): 4781.

https://doi.org/10.1182/blood-2023-186335

Published: 2023

Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Blood (2022) 140 (Supplement 1): 1142–1145.

https://doi.org/10.1182/blood-2022-165524

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)

Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups.

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis

Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis

Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry

Plasma Cell Enumeration By Manual and Automated Methods to Establish a Standard Pictorial Reference

Impact of Socioeconomic Status on Utilisation of ASCT and Overall Survival in Multiple Myeloma: A Report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)

Efficacy and Safety of Isatuximab, Pomalidomide and Dexamethasone in Relapsed AL Amyloidosis: Interim Results of the Isamyp Phase 2 Joint Study from the IFM and ALLG

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Initial Results from the Frailty-Stratified, Randomised Controlled Bayesian Adaptive Trial of Bortezomib Versus Lenalidomide in Transplant Ineligible Myeloma (TI-NDMM) - the FRAIL-M Study (AMaRC 19-01; ALLG MM22)

Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment Accuracy

Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy

Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)

High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL

Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries

A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma

Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only